Brainstorm Cell Therapeutics inc (BCLI) - News Archive

Showing 3 of 3 results.

BrainStorm Cell Therapeutics Surpasses NASDAQ Minimum Market Value Rule, Paving the Way for Revolutionary Neurodegenerative Disease Therapies.

BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value RuleNEW YORK, April 11, 2024 - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI, the Company), a leading developer of cellular therapies fo...

Apr 11, 2024 • Biotechnology & Pharmaceuticals Industry Products & Services NASDAQ

BrainStorm's Revolutionary Allogeneic Exosome Platform-Product Granted Patents, Unlocking New Frontier in Neurological Disorder Treatments

BrainStorm Cell Therapeutics Receives Patents for Allogeneic Exosome Platform-Product, Revolutionizing Neurological Disorder TreatmentsNEW YORK, Dec. 26, 2023 - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a pionee...

Dec 26, 2023 Products & Services NASDAQ

Safeguard Your Investment: Brainstorm Cell Therapeutics Inc. Investors Urged to Act Before January 2 Securities Class Action Deadline

In recent news, the renowned ROSEN Law Firm has issued a call to Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) investors who suffered losses during the Class Period of August 15, 2022, to September 27, 2023. The law...

Dec 25, 2023 Class Action Brainstorm Cell Therapeutics